Pharma News, 2026

Jeito Capital closes its second fund, Jeito II, surpassing its €1bn target to reach over $1.2bn for investing in clinical-stage biopharma companies.

NextCure receives FDA Fast Track Designation for SIM0505, a novel CDH6-targeted ADC for treating platinum-resistant ovarian cancer. Phase 1 data expected.

Foghorn Therapeutics will present new preclinical data for selective SMARCA2 inhibitor FHD-909 and degrader programs at the 2026 AACR Annual Meeting.

Researchers discovered that dermcidin, a natural antimicrobial peptide in the human body, exhibits antiviral activity against the influenza virus.

FDA issued a warning letter to ImmunityBio over misleading promotional claims about Anktiva, including overstated efficacy and omitted risks.

Mayo Clinic reported a dual-drug nanotherapy crossed the blood-brain barrier and improved survival in preclinical glioblastoma models.

Aspect Biosystems secured C$79 million from Canada to support a multi-year cellular medicine project for endocrine and metabolic diseases.

SK biopharmaceuticals will present preclinical data on SKL35501 and SKL35502 at AACR 2026, highlighting its NTSR1-targeted theranostics strategy.

Teva received FDA approval for Ponlimsi, a Prolia biosimilar, while FDA and EMA accepted filings for its proposed Xolair biosimilar.

FDA granted full approval to Tecartus for adults with relapsed or refractory mantle cell lymphoma, expanding use beyond prior BTK inhibitor exposure.

Intelligent Bio Solutions completed a fingerprint-based codeine screen study, supporting a planned FDA 510(k) submission for U.S. clearance.

Adagene and Incyte will start a Phase 1 trial in 2026 testing muzastotug with INCA33890 in third-line MSS colorectal cancer patients.